Additional metabolic benefits
Pritor®/Kinzal® may be able to activate PPAR-γ-Receptor in addition to inhibiting the AT1 receptor. Through this dual mode of action, Pritor®/Kinzal® may influence both blood pressure and other cardiometabolic risk factors.
AT1 receptor inhibition results in significant blood pressure reduction whilst selective PPAR-γ modulation (SPPARM) is suggested to improve associated metabolic parameters including lipid and glucose levels.1
